No Decline in Cognition Scores in Patients with Mild Alzheimer’s Disease Who Received Simufilam Continuously For 24 Months

February 7, 2024

https://www.globenewswire.com/news-release/2024/02/07/2825280/8339/en/No-Decline-in-Cognition-Scores-in-Patients-with-Mild-Alzheimer-s-Disease-Who-Received-Simufilam-Continuously-For-24-Months.html

AUSTIN, Texas, Feb. 07, 2024 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (Nasdaq:SAVA), a biotechnology company, today reported top-line results of a two-year clinical safety study of simufilam, an investigational oral drug for the proposed treatment of Alzheimer’s disease dementia. The study enrolled over 200 patients with mild to moderate Alzheimer’s and consisted of two open-label treatment phases and a randomized, placebo-controlled withdrawal phase. Average changes in ADAS-Cog scores, baseline to month 24, indicate the following:

Read more at globenewswire.com

Related news for (SAVA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.